ArriVent BioPharma, Inc. - 8-K Filing
ArriVent BioPharma reports Q3 2026 results with $393.2M cash runway through mid-2028 and announces leadership transition. (Items: 2.02 Results of Operations and Financial Condition, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 9.01 Financial Statements and Exhibits)
Tickers: $AVBP
Read the full article at SEC EDGAR
Part of the story Zedge, Inc. - 8-K Filing (63 articles)